PCM
TRVI icon

Pinz Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Pinz Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100,355
Closed -$377K – 321
2019
Q4 		$377K Buy
+100,355
New +$376K 0.14% 104

Other funds holding TRVI

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Pinz Capital Management's TRVI Position: Q1 2020 in Review

Pinz Capital Management sold out of Trevi Therapeutics (TRVI) in Q1 2020, closing a stake of 100,355 shares — an estimated $377K sold.

Pinz Capital Management first reported a position in TRVI in Q4 2019 and held it in 1 quarter. The position peaked at $377K in Q4 2019. 20 funds tracked by Wall St. Rank hold TRVI as of Q1 2020.

  • Pinz Capital Management reported no remaining Trevi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Pinz Capital Management sold 100,355 Trevi Therapeutics shares in Q1 2020, an estimated $377K.
  • Pinz Capital Management first reported a position in Trevi Therapeutics in Q4 2019 and held it in 1 quarter.
  • Pinz Capital Management's Trevi Therapeutics position peaked at $377K in Q4 2019.
  • 20 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2020.

Based on Pinz Capital Management's 13F filing for Q1 2020, filed 12 May 2020.